Bioventus Inc Cl A (BVS) Stock Price, Quote & News

Company Profile

Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company's product portfolio includes pain treatments, which comprise various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to treat chronic peripheral pain, and TalisMann provides stimulation to the targeted...

Industry: Medical Devices

Sector: Healthcare

Phone: 919 474 6700

Website: www.bioventus.com

Address:

4721 Emperor Boulevard, Suite 100, Durham, United States

SuperGreenToday May. 1 at 12:29 PM

$BVS Share Price: $9.87 Contract Selected: Oct 16, 2026 $10 Calls Buy Zone: $1.78 – $2.20 Target Zone: $2.95 – $3.60 Potential Upside: 56% ROI Time to Expiration: 167 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

History101 Apr. 25 at 6:30 PM

$BVS 441 watching 4/25/2026

0 · Reply

Doozio Apr. 23 at 7:28 PM

$BVS Thursday 🐑 🎁 s

0 · Reply

OfficialStocktwitsUser Apr. 15 at 9:59 PM

$BVS RSI: 73.97, MACD: 0.2825 Vol: 0.41, MA20: 9.17, MA50: 8.80 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

Doozio Apr. 14 at 2:23 AM

$BVS out of the tightness ONTO 🐒🍌🧠⏰♾️

0 · Reply

Valuebuilder Mar. 17 at 9:47 PM

$BVS Definitely a stock to watch for 2026 as it’s hugely undervalued.Good team in place with a diversified group of products but a complicated story.For the revenue ,margin profile and profitability it’s very cheap on every metric.Has not been discovered by the larger funds yet but when it starts getting attention it can run .

0 · Reply

ClaraDevlin_ Mar. 6 at 8:42 PM

$BVS value area.

0 · Reply

d_risk Mar. 5 at 4:02 PM

$BVS - Bioventus Inc - 10K - Updated Risk Factors BVS overhauled 10-K risks: streamlined financing language; added EGC-to-large issuer, cash concentration, HA/CMS and broader reimbursement and ACA/Medicare cut risks; beefed up IT, cyber, supply chain, litigation, pricing pressure, talent, environmental/sterilization, privacy/export controls and IP litigation disclosures; while dropping explicit competition, branding, training, and some EU MDR detail. #MedicalDevices #HealthcareReimbursement #CybersecurityRisks #SupplyChain #IntellectualProperty 🟢 Added 🟠 Removed https://d-risk.ai/BVS/10-K/2026-03-05

0 · Reply

OpenOutcrier Mar. 5 at 1:45 PM

$BVS (+8.3% pre) Bioventus Earnings Report: Q4 Overview https://ooc.bz/l/95605

0 · Reply

StocktwitsEarnings Mar. 5 at 12:49 PM

$BVS Q4 '25 Earnings Results & Recap • Reported GAAP EPS of $0.22 • Reported revenue of $157.9M up 2.77% YoY • Bioventus expects $2M in annual interest expense savings and extended debt maturity to July 2030 from its 2025 Credit Agreement. The broader market launch of TalisMann and StimTrial products commenced in early 2026.

0 · Reply

Bioventus to Report First Quarter of Fiscal Year 2026 Financial Results on May 6, 2026

Mar 5, 2026, 8:30 AM EST - 2 months ago

Bioventus Earnings Call Transcript: Q4 2025

Mar 5, 2026, 7:00 AM EST - 2 months ago

Bioventus Announces Fourth Quarter and Full Year 2025 Financial Results

Feb 24, 2026, 4:15 PM EST - 2 months ago

Bioventus to Report Fourth Quarter of Fiscal Year 2025 Financial Results on March 5, 2026

Jan 14, 2026, 12:45 PM EST - 3 months ago

Bioventus Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 6, 2026, 7:30 AM EST - 4 months ago

Bioventus to Present at the 44th Annual J.P. Morgan Healthcare Conference

Dec 5, 2025, 3:30 PM EST - 5 months ago

HALPER SADEH LLC ENCOURAGES BIOVENTUS INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS

Dec 3, 2025, 10:10 AM EST - 5 months ago

Bioventus Transcript: Piper Sandler 37th Annual Healthcare Conference

Nov 25, 2025, 4:15 PM EST - 5 months ago

Bioventus to Present at the Piper Sandler 37th Annual Healthcare Conference

Nov 4, 2025, 8:30 AM EST - 6 months ago

Bioventus Earnings Call Transcript: Q3 2025

Nov 4, 2025, 7:30 AM EST - 6 months ago

Bioventus Reports Third Quarter Financial Results

Oct 28, 2025, 7:00 AM EDT - 6 months ago

Bioventus to Report Third Quarter of Fiscal Year 2025 Financial Results on November 4, 2025

Oct 22, 2025, 7:08 PM EDT - 6 months ago

Halper Sadeh LLC Encourages Bioventus Inc. Shareholders to Contact the Firm to Discuss Their Rights

Sep 10, 2025, 1:05 PM EDT - 8 months ago

Bioventus Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 3, 2025, 7:30 AM EDT - 8 months ago

Bioventus to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference

Aug 12, 2025, 2:00 PM EDT - 9 months ago

Bioventus Transcript: Canaccord Genuity’s 45th Annual Growth Conference

Aug 7, 2025, 4:15 PM EDT - 9 months ago

Bioventus to Present at the Canaccord Genuity 45th Annual Global Growth Conference

Aug 6, 2025, 8:30 AM EDT - 9 months ago

Bioventus Earnings Call Transcript: Q2 2025

Aug 6, 2025, 7:00 AM EDT - 9 months ago

Bioventus Reports Second Quarter Financial Results

Aug 4, 2025, 8:00 AM EDT - 9 months ago

Bioventus Enters into a New $400 Million Senior Secured Credit Agreement Lowering Interest Expense and Providing Increased Liquidity

Jul 30, 2025, 7:30 AM EDT - 9 months ago

Bioventus Receives FDA 510(k) Clearances for two Next-Generation Peripheral Nerve Stimulation Products

Jul 29, 2025, 4:15 PM EDT - 9 months ago

Bioventus to Report Second Quarter of Fiscal Year 2025 Financial Results on August 6, 2025

May 6, 2025, 8:30 AM EDT - 1 year ago

Bioventus Earnings Call Transcript: Q1 2025

May 6, 2025, 7:30 AM EDT - 1 year ago

Bioventus Reports First Quarter Financial Results

Apr 28, 2025, 8:00 AM EDT - 1 year ago

Bioventus to Report First Quarter of Fiscal Year 2025 Financial Results on May 6, 2025

Mar 11, 2025, 11:17 AM EDT - 1 year ago

Medical Device Firm Bioventus Stock Jumps On Upbeat 2025 Outlook, Cuts Debt By $48 Million

Mar 11, 2025, 8:30 AM EDT - 1 year ago

Bioventus Earnings Call Transcript: Q4 2024

Mar 11, 2025, 7:30 AM EDT - 1 year ago

Bioventus Announces Fourth Quarter and Full Year 2024 Financial Results

Feb 28, 2025, 7:30 AM EST - 1 year ago

Bioventus to Report Fourth Quarter of Fiscal Year 2024 Financial Results on March 11, 2025

Jan 15, 2025, 1:30 PM EST - 1 year ago

Bioventus Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 2, 2025, 8:00 AM EST - 1 year ago

Bioventus Completes Divestiture of its Advanced Rehabilitation Business to Accelmed Partners

Nov 5, 2024, 8:30 AM EST - 1 year ago

Bioventus Earnings Call Transcript: Q3 2024

Oct 29, 2024, 7:30 AM EDT - 1 year ago

Bioventus to Report Third Quarter of Fiscal Year 2024 Financial Results on November 5, 2024

Aug 21, 2024, 7:37 AM EDT - 1 year ago

Executives Buying W. P. Carey And 2 Other Stocks

WPC GWRS

Aug 14, 2024, 9:00 AM EDT - 1 year ago

Bioventus Transcript: Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 2024

Aug 7, 2024, 4:15 PM EDT - 1 year ago

Bioventus to Present at the Canaccord Genuity 44th Annual Global Growth Conference

Aug 6, 2024, 8:30 AM EDT - 1 year ago

Bioventus Earnings Call Transcript: Q2 2024

Jul 30, 2024, 7:30 AM EDT - 1 year ago

Bioventus to Report Second Quarter of Fiscal Year 2024 Financial Results on August 6, 2024

May 7, 2024, 8:30 AM EDT - 2 years ago

Bioventus Earnings Call Transcript: Q1 2024

Apr 29, 2024, 7:30 AM EDT - 2 years ago

Bioventus to Report First Quarter of Fiscal Year 2024 Financial Results on May 7, 2024

Mar 12, 2024, 8:30 AM EDT - 2 years ago

Bioventus Earnings Call Transcript: Q4 2023

Mar 12, 2024, 7:30 AM EDT - 2 years ago

Bioventus Announces Fourth Quarter and Full Year 2023 Financial Results

Mar 4, 2024, 8:00 AM EST - 2 years ago

Bioventus to Report Fourth Quarter of Fiscal Year 2023 Financial Results on March 12, 2024

Jan 18, 2024, 4:15 PM EST - 2 years ago

Bioventus Enters into an Amendment with its Credit Agreement Lenders to Enhance Financial and Operational Flexibility

Jan 12, 2024, 4:15 PM EST - 2 years ago

Bioventus Announces Inducement Equity to President and Chief Executive Officer Robert Claypoole

Dec 19, 2023, 4:30 PM EST - 2 years ago

Bioventus Names Robert Claypoole as President and Chief Executive Officer

Dec 6, 2023, 8:00 AM EST - 2 years ago

Bioventus Agrees to Nationwide Contract with Aetna™ Medicare Advantage Plans for DUROLANE® for Knee Osteoarthritis

Nov 7, 2023, 8:30 AM EST - 2 years ago

Bioventus Earnings Call Transcript: Q3 2023

Nov 7, 2023, 7:00 AM EST - 2 years ago

Bioventus Reports Third Quarter Financial Results; Raises Full Year 2023 Financial Guidance

Oct 31, 2023, 7:00 AM EDT - 2 years ago

Bioventus to Report Third Quarter of Fiscal Year 2023 Financial Results on November 7, 2023

Sep 19, 2023, 9:52 PM EDT - 2 years ago

Bioventus to Present at the Cantor Global Healthcare Conference

Sep 13, 2023, 8:50 AM EDT - 2 years ago

Bioventus Transcript: Morgan Stanley 21st Annual Global Healthcare Conference 2023

Sep 6, 2023, 4:30 PM EDT - 2 years ago

Bioventus to Present at the Morgan Stanley 21st Annual Global Healthcare Conference

Aug 8, 2023, 8:30 AM EDT - 2 years ago

Bioventus Earnings Call Transcript: Q2 2023

Aug 8, 2023, 7:30 AM EDT - 2 years ago

Bioventus Reports Second Quarter Financial Results; Introduces Full Year 2023 Financial Guidance

Aug 4, 2023, 8:30 AM EDT - 2 years ago

Bioventus to Present at the Canaccord Genuity 43rd Annual Global Growth Conference

Aug 1, 2023, 5:35 PM EDT - 2 years ago

Bioventus to Report Second Quarter of Fiscal Year 2023 Financial Results on August 8, 2023

May 23, 2023, 7:30 AM EDT - 3 years ago

Bioventus Completes Divestiture of its Wound Business

May 16, 2023, 5:00 PM EDT - 3 years ago

Bioventus Earnings Call Transcript: Q1 2023

May 15, 2023, 5:33 PM EDT - 3 years ago

Bioventus Reschedules Reporting of First Quarter Fiscal Year 2023 Financial Results to After Market Close on May 16, 2023

May 11, 2023, 7:00 AM EDT - 3 years ago

Bioventus Reschedules Earnings Call to May 16, 2023; Files for Extension to File Form 10-Q for the Period Ended April 1, 2023

May 10, 2023, 9:00 AM EDT - 3 years ago

Bioventus Announces Divestiture of its Wound Business

May 3, 2023, 8:30 AM EDT - 3 years ago

Bioventus to Report First Quarter of Fiscal Year 2023 Financial Results on May 11, 2023

Apr 5, 2023, 8:00 AM EDT - 3 years ago

Bioventus Announces CEO Leadership Change

Mar 31, 2023, 8:30 AM EDT - 3 years ago

Bioventus Earnings Call Transcript: Q4 2022

Mar 31, 2023, 7:30 AM EDT - 3 years ago

Bioventus Reports Fourth Quarter and Full-Year 2022 Financial Results

Mar 29, 2023, 8:55 AM EDT - 3 years ago

Bioventus Reschedules Reporting of Fourth Quarter Fiscal Year 2022 Financial Results to March 31, 2023

Mar 16, 2023, 8:30 AM EDT - 3 years ago

Bioventus to Report Fourth Quarter of Fiscal Year 2022 Financial Results on March 30, 2023

Mar 12, 2023, 8:50 PM EDT - 3 years ago

INVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in Bioventus Inc. with Losses of $100,000 to Contact the Firm

Jan 11, 2023, 8:15 PM EST - 3 years ago

Bioventus Transcript: JPMorgan Healthcare Conference

Nov 8, 2022, 10:00 AM EST - 3 years ago

Bioventus Earnings Call Transcript: Q3 2022

Aug 11, 2022, 8:30 AM EDT - 4 years ago

Bioventus Earnings Call Transcript: Q2 2022

May 10, 2022, 5:57 AM EDT - 4 years ago

Bioventus Earnings Call Transcript: Q1 2022

Mar 10, 2022, 3:26 PM EST - 4 years ago

Bioventus Earnings Call Transcript: Q4 2021

Nov 8, 2021, 7:00 PM EST - 4 years ago

Bioventus Earnings Call Transcript: Q3 2021

Aug 9, 2021, 8:00 PM EDT - 5 years ago

Bioventus Earnings Call Transcript: Q2 2021

SuperGreenToday May. 1 at 12:29 PM

0 · Reply

History101 Apr. 25 at 6:30 PM

$BVS 441 watching 4/25/2026

0 · Reply

Doozio Apr. 23 at 7:28 PM

$BVS Thursday 🐑 🎁 s

0 · Reply

OfficialStocktwitsUser Apr. 15 at 9:59 PM

0 · Reply

Doozio Apr. 14 at 2:23 AM

$BVS out of the tightness ONTO 🐒🍌🧠⏰♾️

0 · Reply

Valuebuilder Mar. 17 at 9:47 PM

0 · Reply

ClaraDevlin_ Mar. 6 at 8:42 PM

$BVS value area.

0 · Reply

d_risk Mar. 5 at 4:02 PM

0 · Reply

OpenOutcrier Mar. 5 at 1:45 PM

$BVS (+8.3% pre) Bioventus Earnings Report: Q4 Overview https://ooc.bz/l/95605

0 · Reply

StocktwitsEarnings Mar. 5 at 12:49 PM

0 · Reply

StocktwitsEarnings Mar. 5 at 12:49 PM

$BVS Q4 '25 Earnings Results & Recap • Reported GAAP EPS of $0.22 • Reported revenue of $157.9M up 2.77% YoY • Bioventus Inc. expects its 2025 Credit Agreement to provide $2M in annual interest expense savings, increased liquidity, and extended debt maturity to July 2030, enhancing future financial flexibility.

0 · Reply

BillionerOfKing Feb. 27 at 9:42 PM

$BVS Current Stock Price: $8.80 Contracts to trade: $10.0 BVS Mar 20 2026 Call Entry: $0.36 Exit: $0.54 ROI: 49% Hold ~26 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

OfficialStocktwitsUser Feb. 13 at 9:55 PM

$BVS RSI: 60.11, MACD: 0.1391 Vol: 0.22, MA20: 8.07, MA50: 7.76 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

notreload_ai Feb. 9 at 2:47 PM

$DAVE $FRMI $QUIK $BVS -- THE WSJ

0 · Reply

TickerTamer Feb. 4 at 4:02 PM

$BVS is a medical device company (Bioventus Inc.) focused on orthobiologics; it is navigating commercial execution challenges and a heavy debt load.

0 · Reply

BillionerOfKing Jan. 17 at 12:56 AM

$BVS Current Stock Price: $7.93 Contracts to trade: $7.5 BVS Feb 20 2026 Call Entry: $0.81 Exit: $1.50 ROI: 86% Hold ~26 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

CapitalShield Dec. 25 at 3:21 PM

$BVS Macro forces may influence direction, yet internal execution remains the decisive factor. Margin stability needs to accompany any growth acceleration. A series of confirmed wins might reduce the required risk premium. Over time, credibility will hinge on repeatable performance.

0 · Reply

SuperGreenToday Dec. 10 at 3:20 AM

$BVS Share Price: $7.21 Contract Selected: Jul 17, 2026 $10 Calls Buy Zone: $0.66 – $0.81 Target Zone: $1.12 – $1.37 Potential Upside: 60% ROI Time to Expiration: 219 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

NVDAMillionaire Nov. 18 at 11:26 AM

$BVS Brilliant piece that captures BVS's situation perfectly. So if you want to update your understanding of BVS or get to know BVS better, this is essential reading. https://beyondspx.com/quote/BVS/analysis/bioventus-accelerates-growth-and-profitability-with-innovative-musculoskeletal-solutions-bvs

0 · Reply

d_risk Nov. 4 at 6:18 PM

$BVS - Bioventus Inc. Class A Common Stock - 10Q - Updated Risk Factors BVS flags risks from rising rebate claims tied to payer system changes and warns that new government reimbursement reforms could squeeze profitability and impact financial results. #Healthcare #PayerSystemChanges #ProfitabilityPressure #GovernmentRegulation #ReimbursementRisk 🟢 Added 🟠 Removed https://d-risk.ai/BVS/10-Q/2025-11-04

0 · Reply

theDIOyears Oct. 13 at 12:48 PM

$XTNT $BIIB $PHAT $BVS $LGCY In traders jail for the next 90 days. Pray for me.

1 · Reply

Market Cap	820.74M
Revenue (ttm)	568.09M
Net Income (ttm)	22.73M
EPS (ttm)	N/A
PE Ratio	14.22
Forward PE	12.72
Profit Margin	4.00%
Debt to Equity Ratio	1.29

Volume	404,200
Avg Vol	438,562
Day's Range	N/A - N/A
Shares Out	83.16M
Stochastic %K	62%
Beta	0.70
Analysts	Strong Sell
Price Target	$14.80